A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration

Clinical trial NCT03689972 · COMPLETED

Trial details

NCT number: NCT03689972
Sponsor: Biogen
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Multiple Sclerosis, Relapsing-Remitting

Start date: 2018-11-27
Primary completion: 2023-01-31
Enrollment: 585

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.